Clinical Trials Logo
  1. Home
  2. Painful Diabetic Neuropathy
  3. NCT01556152

A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)

Painful Diabetic Neuropathy Clinical Trial

Official title:
A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Neuropathy

Clinical Trial Summary

Diabetic peripheral neuropathy (DPN) represents a diffuse symmetric and length-dependent injury to peripheral nerves that has major implications on quality of life (QOL), morbidity, and costs from a public health perspective. Painful diabetic neuropathy affects 16% of patients with diabetes. Pharmacological agents used in the management of painful DPN mainly include tricyclic antidepressants, selective serotonin and norepinephrine reuptake inhibitors, opioids, and anti epileptic drugs. However, only two drugs (duloxetine and pregabalin) have been formally approved by the EMEA and the US FDA for the treatment of painful DPN. Generally, the available treatment options do not give total relief, are not effective in all patients, and only about one-third of patients may achieve more than 50% pain relief. Hence newer therapies are required for the treatment of DPN.

This is randomized, double-blind, placebo-controlled, parallel group study. The study will include patients with type 1 or type 2 diabetes mellitus with history of pain attributed to DPN for least 6 months and no greater than 5 years.

Patients will be recruited after providing written informed consent.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01556152
Study type Interventional
Source Glenmark Pharmaceuticals Ltd. India
Contact
Status Withdrawn
Phase Phase 2
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT05480228 - EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA Phase 2
Recruiting NCT05476276 - EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy Phase 2
Unknown status NCT01125215 - Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy Phase 2/Phase 3
Not yet recruiting NCT05937984 - Treatment for Painful Diabetic Neuropathy N/A
Recruiting NCT05080530 - Vitamin D and Painful Diabetic Neuropathy N/A
Completed NCT04005287 - A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy Phase 2
Recruiting NCT03331614 - An Evaluation of an SCCD on the Symptomatology of Painful DPN N/A
Recruiting NCT03700528 - The Development of Contextual Cognitive Behavioural Approach to PDN N/A
Recruiting NCT04689984 - The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Recruiting NCT04689971 - The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Recruiting NCT04689958 - The Benefits of Vitamin D 5000 IU as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient Phase 2/Phase 3
Completed NCT03749642 - Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy Phase 2
Not yet recruiting NCT04087941 - Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial Phase 2
Terminated NCT01129960 - Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain Phase 3
Terminated NCT01056315 - A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y Phase 2
Completed NCT00980746 - Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy Phase 2
Completed NCT04786340 - A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy Phase 2
Completed NCT03769675 - Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation N/A
Completed NCT03755934 - Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy Phase 2